查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1717175

多囊性肾病药物市场（按药物类型、给药方式、疾病类型、通路和最终用户划分）－2025-2030 年全球预测

Polycystic Kidney Disease Drugs Market by Drug Type, Mode of Administration, Disease Type, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

多囊性肾病药物市场预计到 2024 年将达到 5.3954 亿美元，2025 年将达到 5.6392 亿美元，到 2030 年将达到 7.0801 亿美元，复合年增长率为 4.63%。

执行摘要简介：为全面了解多囊性肾病变药物奠定基础

主要市场统计数据
基准年2024年 5.3954亿美元
预计2025年 5.6392亿美元
预测年份 2030 7.0801亿美元
复合年增长率（%） 4.63%

多囊性肾病变 (PKD) 带来了复杂的临床挑战，需要持续创新并深入了解市场。该报告首先对当前情况进行了广泛的调查，旨在为需要临床和商业洞察力的相关人员提供清晰、有根据的介绍。 PKD 治疗的不断发展，加上药物开发的最新突破，凸显了该领域正在经历转型期。在这里，我们重点介绍不断发展的治疗方案、临床研究的最新趋势以及影响治疗策略的医疗保健模式的变化。

我们的分析深入研究了过去的市场趋势，并将其与新数据相结合，以帮助专业人士更好地预测和引领 PKD 治疗市场的未来。由于治疗效果和病人安全仍然是这项变革的重中之重，因此介绍将深入探讨变革性的市场变化、关键细分细微差别和区域绩效驱动因素。本报告将为寻求优化治疗策略和发现这个独特市场的成长机会的决策者提供重要资源。

本介绍旨在吸引临床专家、医药负责人、策略规划人员和其他人的注意。准确、全面地了解 PKD 药物治疗的现状，为理解临床创新满足市场需求的复杂生态系统提供了基础。

PKD药物格局正在改变：应对治疗和市场动态的新现实

近年来，PKD 治疗环境一直在变革时期，反映了临床和法规环境的变化。医学研究的进步和新型药物的引入逐渐重新定义了这种多方面疾病的治疗方法。传统的治疗方法已经被更有针对性的治疗方法所取代，这些治疗方法旨在减轻潜在疾病的进展，而不仅仅是控制症状。治疗模式的演变是由严格的临床试验和对 PKD 分子机制的深入了解所推动的。

市场领导者发现的重大转变之一是转向个人化治疗方法。随着临床试验数据的积累，针对特定患者的治疗方案的转变变得越来越明显。这项运动进一步推动了数位健康技术的整合，简化了患者监测和治疗方案的遵守。创新配方的出现也有助于提高疗效并减少副作用的发生，进而改善患者的整体治疗效果。

同时，监管机构透过制定促进创新并确保患者安全的框架来适应这些快速发展。这种平衡的方法促进了有前景的药物的快速核准流程，缩短了先进治疗方案的上市时间。此外，产业和监管机构的积极参与为临床研究人员和製药商共同努力解决未满足的临床需求的更具协作性的环境铺平了道路。

从策略上讲，製药公司正在重新调整投资计划，重点是精准医疗和数位整合等具有高潜在回报的关键领域。这种重新平衡不仅刺激了市场领导者之间的竞争，而且扩大了可用治疗选择的范围。因此，患者护理变得更加个人化和响应性，开创了多囊性肾病管理的新时代。

关键细分洞察揭示药品类型、给药方式、疾病类型、分销管道和最终用户的复杂性

彻底的細項分析揭示了多层次的市场结构，这对于制定有针对性的治疗策略至关重要。就药物类型而言，产品组合多样化，其中血管收缩素II 受体拮抗剂、血管收缩素转化酵素抑制剂和钙通道阻断剂发挥核心作用，同时还有 mTOR 抑制剂、生长抑制素类似物和加压素受体拮抗剂等创新类别。竞争频谱凸显了了解每种药物的独特作用机制和患者适用性的重要性。公司正在加大改良配方的投资，不仅为了提高疗效，也为了优化病人的依从性。

要考虑的另一个方面是管理方法。分析发现，虽然静脉注射和注射给药因其起效迅速而在临床实践中越来越受欢迎，但口服给药因其便利性和患者偏好仍然占据主导地位。这种双重动态要求相关人员在註射疗法的即时有效性与口服疗法的更广泛、更长期的依从性益处之间取得平衡。这些管理上的差异通常决定临床试验的结构并指导新药物传输系统的发展。

疾病类型进一步使市场复杂化，分为常染色体显性多囊性肾病变和常染色体隐性多囊性肾病变。这种分类非常重要，因为它不仅影响患者的人口统计，也影响所需的治疗方法。体染色体显性遗传病例占患者的大多数，需要长期管理方案以减缓病情进展，而体染色体隐性遗传病例则需要更快速、更密集的干预。

細項分析也延伸至销售管道。该市场由包括医院药房、网路药房和零售药房在内的复杂网路支撑。医院药房在急性护理中发挥关键作用，而线上和零售药房则为门诊护理提供了更广泛的管道。这种多通路分销策略旨在优化覆盖范围并确保患者无论身在何处都能及时获得尖端治疗方法。

最后，以诊所、家庭护理机构和医院为重点的最终用户细分揭示了支持 PKD 患者所需的护理水平和资源分配的差异。诊所和医院可以提供由专家主导的即时干预，而家庭护理环境越来越受到远端监控技术和专业药物护理的支持。这些部分相互交织，凸显了市场的复杂性，并促使采取多方面的销售和分销策略来满足每个最终用户场景的特定需求。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 多囊性肾病的盛行率在世界各地不断上升，推动了对创新治疗方法的需求。
      • 加强政府政策和奖励的实施，促进治疗方法的发展
      • 加强病患教育和宣传宣传活动，鼓励病患采取积极主动的疾病管理方法
    • 限制因素
      • 对产品召回和不利事件的担忧
    • 机会
      • 利用 mTOR 抑制剂和加压素受体拮抗剂的进展扩大药物研发管线
      • 扩大伙伴关係关係和合作潜力，开发有效药物
    • 任务
      • 克服新型多囊性肾病变治疗的监管障碍和复杂的核准流程
  • 市场区隔分析
    • 药物类型：mTOR抑制剂在针对细胞增生路径治疗的巨大优势
    • 最终用户：多囊性肾病药物在高发生率都市区诊所的应用快速成长
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

6. 多囊性肾病药物市场（依药物类型）

  • 血管收缩素II 受体阻断剂
  • 血管张力素转化酵素抑制剂
  • 钙离子通道阻断剂
  • mTOR抑制剂
  • 生长抑制素类似物
  • 加压素受体拮抗剂

7. 多囊性肾病药物市场（依给药方式）

  • 静脉注射（IV）或註射
  • 口服

8. 多囊性肾病药物市场（依疾病类型）

  • 常染色体显性多囊性肾病变
  • 常染色体隐性多囊性肾病变

9. 多囊性肾病药物市场（依分销管道）

  • 医院药房
  • 网路药局
  • 零售药局

第 10 章多囊性肾病药物市场（依最终用户）

  • 诊所
  • 居家照护环境
  • 医院

11. 美洲多囊性肾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

12. 亚太多囊肾病药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

13. 欧洲、中东和非洲多囊性肾病药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十四章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Apotex Inc.
  • Boehringer Ingelheim GmbH
  • Centessa Pharmaceuticals Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Fresenius Kabi AG
  • Galapagos NV
  • Kyowa Hakko Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novartis International AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Vertex Pharmaceuticals Incorporated
  • Viatris Inc.
Product Code: MRR-62667ADF9FE1

The Polycystic Kidney Disease Drugs Market was valued at USD 539.54 million in 2024 and is projected to grow to USD 563.92 million in 2025, with a CAGR of 4.63%, reaching USD 708.01 million by 2030.

Executive Summary Introduction: Laying the Groundwork for Comprehensive Insights on Polycystic Kidney Disease Drugs

KEY MARKET STATISTICS
Base Year [2024] USD 539.54 million
Estimated Year [2025] USD 563.92 million
Forecast Year [2030] USD 708.01 million
CAGR (%) 4.63%

Polycystic Kidney Disease (PKD) presents a complex clinical challenge that requires continuous innovation and detailed market understanding. This report commences with an extensive exploration of the current landscape, aiming to offer a clear, well-grounded introduction for stakeholders who demand insight into both clinical and commercial avenues. The evolving dynamics of PKD treatment, coupled with the latest breakthroughs in drug development, underscore a sector in transition. Here, we illuminate the evolution of treatment options, recent developments in clinical research, and the shifting paradigms in healthcare delivery that are influencing treatment strategies.

Our analysis delves into historical market trends and aligns them with emerging data, enabling professionals to better forecast and navigate the future of PKD drug markets. As therapeutic efficacy and patient safety remain at the forefront of this evolution, the introduction sets the stage for a meticulous exploration of transformative market shifts, key segmentation nuances, and regional performance factors. In doing so, the report provides an indispensable resource for decision-makers intent on optimizing treatment strategies and identifying growth opportunities within this specialized market.

This introduction is designed to quickly capture the attention of clinical experts, pharmaceutical marketers, and strategic planners alike. By offering an accurate and comprehensive snapshot of the current state of PKD drug therapies, the ensuing discussions create a foundation for understanding the complex ecosystem where clinical innovation meets market demand.

Transformative Shifts in the PKD Drug Landscape: Navigating New Realities in Treatment and Market Dynamics

In recent years, the PKD drug landscape has undergone transformative shifts that reflect broader changes in both clinical practices and regulatory environments. Advancements in medical research and the introduction of novel pharmacological agents have gradually redefined the approach to treating this multifaceted condition. Traditional therapeutic methodologies have been supplanted by more targeted treatments that not only emphasize the management of symptoms but also aim to mitigate the underlying disease progression. This evolution in treatment paradigms has been driven by robust clinical trials and an increasing understanding of the molecular mechanisms underpinning PKD.

One of the major shifts identified by market leaders is the transition towards therapies that incorporate personalized medicine. As clinical trial data accumulates, a shift toward patient-specific regimens is becoming increasingly apparent. This movement is further supported by the integration of digital health technologies, which are streamlining patient monitoring and adherence to treatment protocols. The emergence of innovative drug formulations has also contributed to better efficacy and lower incidence of adverse side effects, thereby enhancing overall patient outcomes.

Concurrently, regulatory bodies have adapted to these rapid evolutions by developing frameworks that encourage innovation while ensuring patient safety. This balanced approach has facilitated quicker approval processes for promising drugs, thus reducing the time-to-market for advanced therapeutic options. Moreover, the proactive engagement between industry and regulatory authorities has paved the way for a more collaborative environment, in which clinical researchers and pharmaceutical manufacturers work together to address unmet clinical needs.

Strategically, pharmaceutical companies are recalibrating their investment plans to concentrate on key areas that promise high returns, such as precision therapies and digital integration. This recalibration has not only spurred heightened competition among major market players but also expanded the range of available treatment options. As a result, patient care is becoming more individualized and responsive, marking a new era in the management of polycystic kidney disease.

Key Segmentation Insights: Uncovering Intricacies Across Drug Type, Mode of Administration, Disease Type, Distribution Channel, and End-User

Our in-depth segmentation analysis reveals a multilayered market structure that is essential for crafting targeted treatment strategies. Insights into the drug type indicate a well-diversified portfolio, where formulations such as Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, and Calcium Channel Blockers take center stage alongside innovative categories like mTOR Inhibitors, Somatostatin Analogs, and Vasopressin Receptor Antagonists. The competitive spectrum underscores the importance of understanding the unique mechanisms of action and patient suitability for each drug class. Companies are increasingly investing in enhanced formulations that not only improve efficacy but also optimize patient adherence.

Another dimension that merits attention is the mode of administration. Analysis shows that while intravenous or injectable options are gaining traction in clinical settings due to their rapid onset of action, oral administration continues to dominate given its convenience and patient preference. This dual dynamic requires stakeholders to balance the immediate impact of injectable therapies with the broader, long-term compliance benefits of oral regimens. The distinctions between these modes often dictate the structuring of clinical trials and direct the development of new drug delivery systems.

Disease type further complicates the market landscape, where a bifurcation is observed between Autosomal Dominant Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease. This classification is critical as it not only affects the patient demographic but also influences the therapeutic modality required. Autosomal Dominant cases, which represent a significant share of the patient pool, necessitate long-term management solutions aimed at slowing disease progression, while Autosomal Recessive instances call for more immediate, intensive intervention.

The segmentation analysis extends into the distribution channel. The market is supported by an intricate network involving hospital pharmacies, online pharmacies, and retail pharmacies. Each channel has its distinct set of drivers, with hospital pharmacies playing a crucial role in acute care settings, and online or retail channels providing wide accessibility to outpatient treatments. This multi-channel distribution strategy is crafted to optimize reach and ensure that patients have timely access to cutting-edge therapies wherever they are located.

Lastly, the end-user segmentation that focuses on clinics, homecare settings, and hospitals reveals insights into the differing levels of care and resource allocation necessary to support PKD patients. Clinics and hospitals can facilitate immediate, expert-driven interventions, while homecare settings are increasingly being supported by remote monitoring technologies and specialized pharmaceutical care. The intertwined nature of these segments underscores the complexity of the market, driving a multi-pronged approach to sales and distribution strategies that cater to the specific needs of each end-user scenario.

Based on Drug Type, market is studied across Angiotensin II Receptor Blockers, Angiotensin-Converting Enzyme Inhibitors, Calcium Channel Blockers, mTOR Inhibitors, Somatostatin Analogs, and Vasopressin Receptor Antagonists.

Based on Mode of Administration, market is studied across Intravenous (IV) or Injectable and Oral.

Based on Disease Type, market is studied across Autosomal Dominant Polycystic Kidney Disease and Autosomal Recessive Polycystic Kidney Disease.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.

Based on End-User, market is studied across Clinics, Homecare Settings, and Hospitals.

Key Regional Insights: Analyzing Market Dynamics Across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional analysis of the PKD market highlights significant variations in market dynamics, regulatory environments, and healthcare infrastructure. In the Americas, the market is bolstered by robust healthcare funding, advanced clinical infrastructure, and a strong focus on research and development. This region is characterized by a proactive adoption of innovative treatment methodologies and a comprehensive healthcare system that supports both acute and chronic care models.

In the Europe, Middle East & Africa region, a diverse mix of emerging markets and established healthcare systems creates a dynamic environment where progressive regulatory reforms align with growing investments in healthcare. The region is notable for its balanced approach to cost control and the adoption of advanced therapeutic options. Driven by heightened public awareness and governmental support, this region is steadily gaining ground in terms of market penetration and clinical outcomes.

In the Asia-Pacific region, rapid economic growth coupled with an expanding middle class has led to increased healthcare investments. The region is witnessing an accelerated adoption of novel therapeutic solutions, propelled by advancements in pharmaceutical manufacturing and burgeoning research and development initiatives. This growth is further accelerated by government policies that encourage innovation in drug discovery and a strong focus on patient-centric care models. The contrasting healthcare environments across these regions underscore the need for tailored strategies that respect local nuances while leveraging global best practices.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Company Insights: Market Leaders Shaping the Future of PKD Therapeutics Through Strategic Vision and Innovation

A review of key companies in the PKD drug market reveals how strategic vision and innovative approaches are catalyzing the development of next-generation therapies. Market leaders such as Apotex Inc. and Boehringer Ingelheim GmbH have long been at the forefront of drug development, harnessing advanced research platforms to push the boundaries of traditional treatment approaches. Centessa Pharmaceuticals Limited and Eli Lilly and Company are leveraging deep clinical expertise to refine patient-focused therapies, while F. Hoffmann-La Roche AG and Fresenius Kabi AG continue to invest heavily in improving drug safety profiles and enhancing the therapeutic index of existing compounds.

Innovation is equally palpable among emerging players like Galapagos NV and Kyowa Hakko Kirin Co., Ltd., whose research into novel mechanisms of action is opening up new therapeutic pathways. Merck & Co., Inc. and Mitsubishi Tanabe Pharma Corporation have robust portfolios that reflect years of clinical experience and a commitment to patient-centric care, further reinforced by the strategic investments made by Novartis International AG and Otsuka Pharmaceutical Co., Ltd. These organizations not only emphasize product efficacy but also prioritize integrated healthcare solutions that encompass patient support services.

The competitive landscape is rounded out by cutting-edge companies such as Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, and Viatris Inc., all of which are making significant contributions to the field of PKD therapeutics. Their work is characterized by rigorous clinical studies, an emphasis on precision medicine, and the development of digital health tools that enhance patient engagement. Collectively, these companies are driving a landscape where innovation and market responsiveness are interwoven, ensuring that therapeutic advancements are delivered effectively to meet diverse patient needs.

The report delves into recent significant developments in the Polycystic Kidney Disease Drugs Market, highlighting leading vendors and their innovative profiles. These include Apotex Inc., Boehringer Ingelheim GmbH, Centessa Pharmaceuticals Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Fresenius Kabi AG, Galapagos NV, Kyowa Hakko Kirin Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novartis International AG, Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, and Viatris Inc.. Actionable Recommendations: Strategic Considerations to Propel Market Growth and Strengthen Competitive Advantage in PKD Drugs

Industry leaders are encouraged to adopt a multi-dimensional strategy that aligns clinical innovation with market dynamics. First and foremost, there is a pressing need to maintain a patient-centric focus. Investment in personalized medicine should be prioritized to tailor therapies based on the specific genetic and clinical profiles of PKD patients. Embracing digital health solutions that facilitate remote patient monitoring and data-driven decision-making can further enhance this personalization.

Simultaneously, companies should consider diversifying their drug portfolios by advancing research in both traditional therapies and novel treatments. Integrating clinical trials that combine innovative therapeutic modalities with environmental and genetic data will help in carving out competitive niches. It is also advisable to develop strategic alliances with academic institutions, technology firms, and regional healthcare providers. This collaborative approach not only enriches research capabilities but also speeds up the transition of promising drug candidates from laboratory settings to commercial viability.

Furthermore, optimizing distribution channel strategies is critical. Firms must adopt robust, multi-modal distribution frameworks that ensure swift access to therapies across hospital pharmacies, online platforms, and retail outlets. This requires a balanced logistical structure that supports both centralized and decentralized distribution modes. Additionally, fostering relationships with healthcare providers operating in clinics, homecare settings, and hospitals can help in streamlining the delivery of new treatments, thereby enhancing market penetration.

Regulatory agility is another cornerstone of a proactive business strategy. Companies should develop dedicated regulatory teams that are equipped to navigate the evolving global landscape. By engaging in consistent dialogue with regulatory bodies and adopting best practices from regions with progressive guidelines, organizations can mitigate potential delays in drug approval processes, ultimately contracting the time-to-market for innovative therapies.

Lastly, leveraging market analytics and segmentation insights is vital for tailoring product development and marketing strategies. Understanding the nuanced differences across drug types, modes of administration, and disease classifications enables companies to better position their offerings. An analytical approach that integrates real-world data and consumer feedback will allow for the customization of strategic actions and drive sustainable growth in a competitive market environment.

Conclusion: Synthesizing Critical Insights and Implications for the Future of PKD Drug Therapies

In summary, the evolving landscape of polycystic kidney disease drugs is defined by rapid advancements in clinical research, strategic market realignments, and an ongoing shift toward patient-centric care. This comprehensive analysis highlights the importance of a multifaceted approach that integrates clinical breakthroughs with strategic segmentation. The detailed examination of drug type, mode of administration, disease category, distribution channel, and end-user perspectives reveals critical performance benchmarks and growth opportunities that are reshaping the market.

Moreover, regional insights indicate that while the Americas and Europe, Middle East & Africa continue to lead with established healthcare systems and research infrastructures, the Asia-Pacific region emerges as a dynamic hotspot with significant growth potential. Meanwhile, leading companies are setting the pace for innovative therapeutics by harnessing robust R&D frameworks, deep clinical expertise, and agile regulatory strategies.

The synthesis of these insights underscores a clear imperative for industry stakeholders: to continuously realign their strategies in response to emerging trends, to invest in groundbreaking research, and to enhance patient support mechanisms across all channels. The future trajectory of PKD drug therapies is set to benefit from this integrated approach, paving the way for more effective, targeted treatments that address the pressing clinical needs of a diverse patient population.

This conclusion serves as a call for sustained innovation and strategic foresight as the market continues to evolve. It emphasizes that success in this arena will depend on the ability to adapt to changing clinical paradigms while maintaining a relentless focus on patient outcomes and technological integration.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of polycystic kidney disease worldwide is fueling need for innovative treatments
      • 5.1.1.2. Growing implentation of government policies and incentives for the development of treatments
      • 5.1.1.3. Increasing patient education and awareness campaigns encouraging proactive approaches to disease management
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with product recall and adverse findings of drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Expansion of the drug pipeline with advancements for mTOR inhibitors and vasopressin receptor antagonists
      • 5.1.3.2. Growing potential with partnerships and collaborations for the development of effective drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Navigating regulatory hurdles and complex approval processes for new polycystic kidney disease drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Significant benefits of mTOR inhibitors for targeting cellular growth pathways in treatment
    • 5.2.2. End-User: Proliferating applications of polycystic kidney disease drugs in clinics for high disease prevalence in urban settings
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Polycystic Kidney Disease Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Angiotensin II Receptor Blockers
  • 6.3. Angiotensin-Converting Enzyme Inhibitors
  • 6.4. Calcium Channel Blockers
  • 6.5. mTOR Inhibitors
  • 6.6. Somatostatin Analogs
  • 6.7. Vasopressin Receptor Antagonists

7. Polycystic Kidney Disease Drugs Market, by Mode of Administration

  • 7.1. Introduction
  • 7.2. Intravenous (IV) or Injectable
  • 7.3. Oral

8. Polycystic Kidney Disease Drugs Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Autosomal Dominant Polycystic Kidney Disease
  • 8.3. Autosomal Recessive Polycystic Kidney Disease

9. Polycystic Kidney Disease Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Polycystic Kidney Disease Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Homecare Settings
  • 10.4. Hospitals

11. Americas Polycystic Kidney Disease Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Polycystic Kidney Disease Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Polycystic Kidney Disease Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Regulus Therapeutics announces promising ADPKD results and FDA alignment for Farabursen
    • 14.3.2. Mitsui Chemicals invests in Rege Nephro to advance kidney disease therapies
    • 14.3.3. Maze Therapeutics launches phase 1 Trial for novel CKD treatment MZE782
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Apotex Inc.
  • 2. Boehringer Ingelheim GmbH
  • 3. Centessa Pharmaceuticals Limited
  • 4. Eli Lilly and Company
  • 5. F. Hoffmann-La Roche AG
  • 6. Fresenius Kabi AG
  • 7. Galapagos NV
  • 8. Kyowa Hakko Kirin Co., Ltd.
  • 9. Merck & Co., Inc.
  • 10. Mitsubishi Tanabe Pharma Corporation
  • 11. Novartis International AG
  • 12. Otsuka Pharmaceutical Co., Ltd.
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Teva Pharmaceutical Industries Ltd.
  • 16. Vertex Pharmaceuticals Incorporated
  • 17. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET MULTI-CURRENCY
  • FIGURE 2. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET MULTI-LANGUAGE
  • FIGURE 3. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 4. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CALCIUM CHANNEL BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY SOMATOSTATIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY VASOPRESSIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY INTRAVENOUS (IV) OR INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 238. POLYCYSTIC KIDNEY DISEASE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024